WO2026002032 - PIM KINASE INHIBITOR
National phase entry is expected:
Publication Number
WO/2026/002032
Publication Date
02.01.2026
International Application No.
PCT/CN2025/103410
International Filing Date
25.06.2025
Title **
[English]
PIM KINASE INHIBITOR
[French]
INHIBITEUR DE KINASE PIM
[Chinese]
一种PIM激酶抑制剂
Applicants **
HANGZHOU BANGSHUN PHARMACEUTICAL CO., LTD.
Inventors
WEN, Qiaodong
YANG, Xin
CUI, Rong
ZHENG, Mei
BAO, Yuehua
YIN, Jianming
LV, Yubin
Priority Data
202410825802.X
25.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2015 | |
| EPO | Filing, Examination, Granting | 12741 | |
| Japan | Filing, Examination, Granting | 2181 | |
| South Korea | Filing, Examination, Granting | 2107 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,784
Contact Us
Abstract[English]
Disclosed in the present invention are a PIM kinase inhibitor as shown in general formula II, a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the preparation of a drug for preventing and/or treating indications related to a PIM signaling pathway. The compound of the present invention is an ideal PIM kinase inhibitor with a high activity, which can be used for treating and/or preventing diseases including autoimmune diseases and tumors, e.g., inflammatory bowel disease, hematologic malignancies such as acute myeloid leukemia, myelofibrosis and chronic lymphocytic leukemia, and solid tumors such as gastric cancer and prostate cancer.[French]
La présente invention concerne un inhibiteur de kinase PIM tel que représenté dans la formule générale II, une composition pharmaceutique de celui-ci, son procédé de préparation et son utilisation dans la préparation d'un médicament pour la prévention et/ou le traitement d'indications relatives à une voie de signalisation PIM. Le composé de la présente invention est un inhibiteur idéal de kinase PIM ayant une activité élevée, lequel peut être utilisé pour traiter et/ou prévenir des maladies parmi lesquelles figurent des maladies auto-immunes et des tumeurs, par exemple, la maladie intestinale inflammatoire, des malignités hématologiques telles que la leucémie myéloïde aiguë, la myélofibrose et la leucémie lymphoïde chronique, et des tumeurs solides telles que le cancer gastrique et le cancer de la prostate.[Chinese]
本发明公开了一种通式II所示的PIM激酶抑制剂，其药物组合物、制备方法及其在制备、预防和/或治疗与PIM信号通路相关适应症的药物的用途。本发明的化合物是理想的高活性PIM激酶抑制剂，可用于治疗和/或预防的疾病，包括自身免疫疾病和肿瘤，例如炎症性肠炎、急性髓系白血病、骨髓纤维化、慢性淋巴细胞性白血病等血液瘤以及胃癌、前列腺癌等实体瘤。